Brigatinib
Generic Details
Generic Name
Brigatinib
Other Names
- Brigatinib sulfate
Drug Class
- Antineoplastic agent
- Tyrosine kinase inhibitor
Chemical Formula
C29H39ClN7O2S
Molecular Weight
584.19 g/mol
Mechanism of Action
- Inhibits anaplastic lymphoma kinase (ALK)
- Inhibits receptor tyrosine kinase (RTK)
Indications
- Treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC)
- Treatment of ALK-positive metastatic NSCLC resistant to crizotinib
Common Dosage Forms
- Tablet
Typical Dosage
- 90 mg orally once daily for 7 days, then 180 mg orally once daily
Pediatric Dosage
Geriatric Dosage
- Use with caution, no specific dosage adjustments recommended
Side Effects
- Fatigue
- Nausea
- Diarrhea
- Cough
- Increased blood creatinine levels
- Pulmonary embolism
Contraindications
- Hypersensitivity to brigatinib or any component of the formulation
Pregnancy Category
- Category D - Positive evidence of risk
- Avoid use in pregnancy
Lactation Safety
- Not recommended to breastfeed during treatment with brigatinib
Drug Interactions
- Strong CYP3A inhibitors can increase brigatinib levels
- Strong CYP3A inducers can decrease brigatinib levels
Overdose Symptoms
- Bradycardia
- Hypertension
- Fatigue
- Nausea
Antidote for Overdose
- No specific antidote, manage symptoms and provide supportive care
Storage Conditions
- Store at room temperature (20-25°C)
- Protect from moisture and light
Pharmacokinetics
- Absorption: Well absorbed orally, peak plasma concentrations reached in 4 hours
- Distribution: Extensively distributed in tissues
- Metabolism: Metabolized in the liver primarily by CYP2C8 and CYP3A4
- Excretion: Mainly excreted in feces and urine
Precautions
- Monitor for interstitial lung disease
- Monitor for hypertension
- Monitor for cardiac function
Warnings
- Risk of interstitial lung disease
- Hypertension
- Bradycardia
- Pulmonary embolism
Others
- Regular monitoring of liver function tests recommended during treatment